Who
Phil Tennant
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Precigen.
In numbers
- Trades disclosed
- 39
- Buys
- 1
- Sells
- 2
- Bought
- $21K
- Sold
- $1.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Jul 2024
- Last trade
- 25 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Sep 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | $127K79,166 at $1.61 | filing |
| 25 Aug 2026filed 25 Aug 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —79,166 at $0.00 | filing |
| 25 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $594K79,166 at $7.50 | filing |
| 25 Aug 2026filed 25 Aug 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —79,166 at $0.00 | filing |
| 25 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | $127K79,166 at $1.61 | filing |
| 25 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $594K79,166 at $7.50 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —5,208 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code F | $19K2,585 at $7.20 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,208 at $0.00 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,208 at $0.00 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —5,208 | filing |
| 23 Aug 2026filed 25 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code F | $19K2,585 at $7.20 | filing |
| 28 May 2026filed 1 Jun 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $132K30,272 at $4.36 | filing |
| 28 May 2026filed 1 Jun 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $132K30,272 at $4.36 | filing |
| 23 May 2026filed 27 May 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —62,500 | filing |
| 23 May 2026filed 27 May 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,500 at $0.00 | filing |
| 23 May 2026filed 27 May 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,500 at $0.00 | filing |
| 23 May 2026filed 27 May 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Code M | —62,500 | filing |
| 20 Apr 2026filed 22 Apr 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —385,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | PGEN Precigenoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.